{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:00:34Z","timestamp":1776459634186,"version":"3.51.2"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant funded by the Korean government","award":["RS-2021-NR059198"],"award-info":[{"award-number":["RS-2021-NR059198"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Mild cognitive impairment (MCI), an intermediate condition between healthy cognitive changes due to aging and dementia, is a risk factor for dementia. Cheonwangbosim-dan (CWBSD) is a traditional herbal medicine widely used to improve mental and physical illness in East Asia. We aimed to investigate the safety and efficacy of CWBSD in the treatment of MCI. This clinical trial adopted a double-blind, single-center, parallel-arm, prospective, randomized controlled pilot study design with a full analysis set. Forty-eight participants with MCI were randomized to the control or CWBSD groups. The participants were administered either placebo or CWBSD once daily (at a dose of 3\u2009g) for twenty-four weeks. The primary outcome measure was a change in the Korean version of the Montreal Cognitive Assessment Scale (MoCA-K). The secondary outcome measures included memory, quality of life, depression, and level of activity in daily living. Safety measures were conducted by comparing the occurrence of adverse events and changes in blood chemistry parameters, pulse rate, and blood pressure between the two groups. After 24 weeks of treatment, no significant differences in the changes in the total MoCA-K scores were detected between the two groups. Changes in secondary outcomes were not significantly different between the two groups. In the safety evaluation, there was no significant difference between the two groups with regard to the occurrence of adverse events and changes in blood chemistry parameters, blood pressure, and pulse rate. We demonstrated that CWBSD treatment may be safe and does not significantly improve cognitive function, quality of life, daily activities, or depression in individuals with MCI. Further studies are necessary to validate the efficacy and safety of CWBSD in the treatment of MCI.<\/jats:p>\n<jats:p>Trial registration<\/jats:p>\n<jats:p>Clinical Research Information Service KCT0006787.<\/jats:p>","DOI":"10.1371\/journal.pone.0326227","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:51:33Z","timestamp":1752256293000},"page":"e0326227","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of Cheonwangbosim-dan (Tian Wang Bu Xin Dan) for treatment of mild cognitive impairment: A randomized placebo-controlled pilot trial"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4806-3401","authenticated-orcid":true,"given":"Jae-Hong","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ae-Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-2078","authenticated-orcid":true,"given":"Bok-Nam","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwang-Cheon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Soon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"3","key":"pone.0326227.ref001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/joim.12190","article-title":"Mild cognitive impairment: a concept in evolution","volume":"275","author":"RC Petersen","year":"2014","journal-title":"J Intern Med"},{"issue":"4","key":"pone.0326227.ref002","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cger.2018.06.005","article-title":"Mild cognitive impairment in geriatrics","volume":"34","author":"EG Tangalos","year":"2018","journal-title":"Clin Geriatr Med"},{"issue":"3","key":"pone.0326227.ref003","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archneur.58.3.397","article-title":"Mild cognitive impairment represents early-stage Alzheimer disease","volume":"58","author":"JC Morris","year":"2001","journal-title":"Arch Neurol"},{"issue":"4","key":"pone.0326227.ref004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1212\/WNL.0000000000000055","article-title":"Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal","volume":"82","author":"RO Roberts","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"pone.0326227.ref005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/01.wnl.0000224748.48011.84","article-title":"Conversion to dementia from mild cognitive disorder: the Cache County Study","volume":"67","author":"JT Tschanz","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"pone.0326227.ref006","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp-2014-310095","article-title":"Risk factors for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease: a systematic review and meta-analysis of cohort studies","volume":"87","author":"J-Q Li","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"pone.0326227.ref007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1017\/S1092852918001347","article-title":"State of the science on Mild Cognitive Impairment (MCI)","volume":"24","author":"ND Anderson","year":"2019","journal-title":"CNS Spectr"},{"issue":"12","key":"pone.0326227.ref008","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study","volume":"5","author":"L Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"pone.0326227.ref009","doi-asserted-by":"crossref","first-page":"719849","DOI":"10.3389\/fneur.2021.719849","article-title":"Diagnosis and treatment for mild cognitive impairment: a systematic review of clinical practice guidelines and consensus statements","volume":"12","author":"Y-X Chen","year":"2021","journal-title":"Front Neurol"},{"issue":"8","key":"pone.0326227.ref010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/15622975.2019.1696473","article-title":"Management of Mild Cognitive Impairment (MCI): the need for national and international guidelines","volume":"21","author":"S Kasper","year":"2020","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"pone.0326227.ref011","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"RC Petersen","year":"2018","journal-title":"Neurology"},{"key":"pone.0326227.ref012","doi-asserted-by":"crossref","first-page":"642128","DOI":"10.1155\/2014\/642128","article-title":"History and experience: a survey of traditional chinese medicine treatment for Alzheimer\u2019s disease","volume":"2014","author":"P Liu","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"issue":"3","key":"pone.0326227.ref013","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10522-012-9375-6","article-title":"Evaluating the traditional Chinese literature for herbal formulae and individual herbs used for age-related dementia and memory impairment","volume":"13","author":"BH May","year":"2012","journal-title":"Biogerontology"},{"key":"pone.0326227.ref014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.trci.2019.03.001","article-title":"Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: a 52-week randomized controlled trial","volume":"5","author":"J Tian","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"pone.0326227.ref015","doi-asserted-by":"crossref","first-page":"104319","DOI":"10.1016\/j.phrs.2019.104319","article-title":"Long-term efficacy of Chinese medicine Bushen Capsule on cognition and brain activity in patients with amnestic mild cognitive impairment","volume":"146","author":"J Zhang","year":"2019","journal-title":"Pharmacol Res"},{"issue":"1","key":"pone.0326227.ref016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12906-021-03428-6","article-title":"Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial","volume":"21","author":"H-Y Shin","year":"2021","journal-title":"BMC Complement Med Ther"},{"issue":"10","key":"pone.0326227.ref017","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/ptr.5679","article-title":"Chinese herbal medicine for mild cognitive impairment: a systematic review and meta-analysis of cognitive outcomes","volume":"30","author":"L Dong","year":"2016","journal-title":"Phytother Res"},{"key":"pone.0326227.ref018","doi-asserted-by":"crossref","first-page":"903224","DOI":"10.3389\/fneur.2022.903224","article-title":"Chinese herbal medicine for mild cognitive impairment: a systematic review of randomized controlled trials","volume":"13","author":"N Liang","year":"2022","journal-title":"Front Neurol"},{"key":"pone.0326227.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4260801","article-title":"Tian Wang Bu Xin Dan for Insomnia: a systematic review of efficacy and safety","volume":"2019","author":"X Yang","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"pone.0326227.ref020","doi-asserted-by":"crossref","first-page":"1534735420935643","DOI":"10.1177\/1534735420935643","article-title":"Comparative effectiveness of Cheonwangbosimdan (Tian Wang Bu Xin Dan) versus cognitive-behavioral therapy for insomnia in cancer patients: a randomized, controlled, open-label, parallel-group, pilot trial","volume":"19","author":"S-Y Moon","year":"2020","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"pone.0326227.ref021","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/jpm11050325","article-title":"The herbal formula CWBSD improves sleep quality dependent on oral microbial type and tongue diagnostic features in Insomnia","volume":"11","author":"M-J Kim","year":"2021","journal-title":"J Pers Med"},{"key":"pone.0326227.ref022","first-page":"15","article-title":"The effects of Cheonwangbosim-dan and herbs on mouse neuroblastoma 2a cells damaged by hypoxia-reoxygenation","volume":"17","author":"SH Kim","year":"2006","journal-title":"J Orient Neuropsychiatry"},{"key":"pone.0326227.ref023","first-page":"77","article-title":"The effects of Chenwangbosimdan (CBD) hot water extract & ultra-fine powder on the Alzheimer\u2019s disease model","volume":"19","author":"KW Choi","year":"2008","journal-title":"J Orient Neuropsychiatry"},{"key":"pone.0326227.ref024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13020-016-0086-9","article-title":"Patterns of Chinese medicine use in prescriptions for treating Alzheimer\u2019s disease in Taiwan","volume":"11","author":"S-K Lin","year":"2016","journal-title":"Chin Med"},{"key":"pone.0326227.ref025","first-page":"8820705","article-title":"Effectiveness and safety of the Korean Medicine Senior Health Promotion Program using herbal medicine and acupuncture for mild cognitive impairment: a retrospective study of 500 patients in Seoul, Korea","volume":"2021","author":"H-W Suh","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"issue":"10","key":"pone.0326227.ref026","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.21037\/apm-22-701","article-title":"Cognitive improvement effects of Tian Wang Bu Xin Dan (Cheonwangbosimdan) in patients with mild cognitive impairment: protocol for a randomized placebo-controlled pilot clinical trial","volume":"11","author":"J-H Kim","year":"2022","journal-title":"Ann Palliat Med"},{"key":"pone.0326227.ref027","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5\u2122","author":"American Psychiatric Association. DSM-5 Task Force","year":"2013"},{"issue":"4","key":"pone.0326227.ref028","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"ZS Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"pone.0326227.ref029","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0891988708316855","article-title":"Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment","volume":"21","author":"J-Y Lee","year":"2008","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"4","key":"pone.0326227.ref030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4306\/pi.2008.5.4.232","article-title":"Standardization of the korean version of the geriatric depression scale: reliability, validity, and factor structure","volume":"5","author":"JY Kim","year":"2008","journal-title":"Psychiatry Investig"},{"issue":"9","key":"pone.0326227.ref031","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/gps.699","article-title":"Development of the Korean version of Alzheimer\u2019s Disease Assessment Scale (ADAS-K)","volume":"17","author":"JC Youn","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"pone.0326227.ref032","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-cog): modifications and responsiveness in pre-dementia populations. A narrative review","volume":"63","author":"JK Kueper","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"pone.0326227.ref033","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s11136-012-0331-3","article-title":"Psychometric properties of the EQ-5D-5L in the general population of South Korea","volume":"22","author":"TH Kim","year":"2013","journal-title":"Qual Life Res"},{"issue":"7","key":"pone.0326227.ref034","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s11136-015-1205-2","article-title":"The EQ-5D-5L valuation study in Korea","volume":"25","author":"S-H Kim","year":"2016","journal-title":"Qual Life Res"},{"issue":"4","key":"pone.0326227.ref035","first-page":"273","article-title":"The validity and reliability of Korean Instrumental Activity of Daily Living (K-IADL) scale","volume":"6","author":"CW Won","year":"2002","journal-title":"J Korean Geriatr Soc"},{"key":"pone.0326227.ref036","first-page":"98","article-title":"The validity and reliability of Korean Activity of Daily Living (K-ADL) scale","volume":"6","author":"CW Won","year":"2002","journal-title":"J Korean Geriatr Soc"},{"issue":"4","key":"pone.0326227.ref037","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pst.185","article-title":"Sample size of 12 per group rule of thumb for a pilot study","volume":"4","author":"SA Julious","year":"2005","journal-title":"Pharm Stat"},{"key":"pone.0326227.ref038","doi-asserted-by":"crossref","first-page":"4251747","DOI":"10.1155\/2017\/4251747","article-title":"Efficacy and safety of an herbal therapy in patients with amnestic mild cognitive impairment: a 24-week randomized phase III trial","volume":"2017","author":"J Tian","year":"2017","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"pone.0326227.ref039","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12906-022-03805-9","article-title":"Effects of Kami Guibi-tang in patients with mild cognitive impairment: study protocol for a phase III, randomized, double-blind, and placebo-controlled trial","volume":"22","author":"H-Y Shin","year":"2022","journal-title":"BMC Complement Med Ther"},{"issue":"11","key":"pone.0326227.ref040","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1177\/0733464814566852","article-title":"A review of self-management interventions for people with dementia and mild cognitive impairment","volume":"35","author":"C Quinn","year":"2016","journal-title":"J Appl Gerontol"},{"issue":"3","key":"pone.0326227.ref041","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jep.2012.01.033","article-title":"Syndrome differentiation in modern research of traditional Chinese medicine","volume":"140","author":"M Jiang","year":"2012","journal-title":"J Ethnopharmacol"},{"key":"pone.0326227.ref042","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/NDT.S290692","article-title":"Characteristics of TCM constitution and related biomarkers for mild cognitive impairment","volume":"17","author":"X Deng","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"pone.0326227.ref043","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/NDT.S333569","article-title":"Herbal medicine for patients with cognitive impairment: an observational study","volume":"17","author":"Y Choi","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"pone.0326227.ref044","doi-asserted-by":"crossref","first-page":"4323989","DOI":"10.1155\/2020\/4323989","article-title":"Korean traditional medicine in treating patients with mild cognitive impairment: a multicenter prospective observational case series","volume":"2020","author":"Y Choi","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"pone.0326227.ref045","doi-asserted-by":"crossref","first-page":"28982","DOI":"10.1038\/srep28982","article-title":"A two-year treatment of amnestic mild cognitive impairment using a compound Chinese medicine: a placebo controlled randomized trial","volume":"6","author":"J Zhang","year":"2016","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:51:51Z","timestamp":1752256311000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326227"}},"subtitle":[],"editor":[{"given":"Muhammad Salman","family":"Bashir","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0326227","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}